

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

RECEIVED.
SECRETARY OF THE SENATE

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name Pfizer Inc			
2. Address <input type="checkbox"/> Check if different than previously reported 325 7th Street, NW Suite 1200 Washington DC 20004 USA			
3. Principal place of business (if different than line 2) City _____ State/Zip or Country _____			
4a. Contact Name	b. Telephone number	c. E-mail	5. Senate ID #
Mr. Richard H. Bagger	(202) 783-7070	rich.bagger@pfizer.com	31326-12
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID #
Pfizer Inc			31354000

TYPE OF REPORT 8. Year 2005 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇨ Termination Date _____ 11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000

\$10,000 or more ⇨ \$ _____

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000

\$10,000 or more ⇨ \$ 3,490,000

14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options

Method A. Reporting amounts using LDA definitions on Internal Revenue Code

Method B. Reporting amounts under section 6033(b)(8), Internal Revenue Code

Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

0000061699

i Edit Form > File with

Senate Password File with

Signature *Richard H. Bagger* Date 2/13/2006

Printed Name and Title Richard H. Bagger - Senior Vice President, Government Relations



Registrant Name Pfizer Inc

Client Name Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code AGR - Agriculture (one per page)

16. Specific lobbying issues

H.R. 2206, Veterinary Workforce Expansion Act of 2005, pharmaceutical counterfeiting, importation
H.R. 2744, Agriculture Appropriations, pharmaceutical counterfeiting, importation
S. 914, Veterinary Workforce Expansion Act of 2005, pharmaceutical counterfeiting, importation


17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

	Name	Covered Official Position (if applicable)
	Richard H. Bagger	
	Catherine P. Bennett	
	Michael D. Boyd	
	Kimberly Miller Davis	
	Dolly Judge	
	Louis A. LaMarca	
	McCarthy Justin	
	Wilson Anne	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 2/13/06

0000061700

Registrant Name Pfizer Inc

Client Name Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code ANI - Animals (one per page)

16. Specific lobbying issues

animal health (no bills)

17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Ron Roberts	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

1000061701

00

Printed Name and Title Richard H. Bagger - Senior Vice President, Government Relations

LD-2DS (Rev. 4.06)

Page 3

Registrant Name Pfizer Inc

Client Name Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code BUD - Budget/Appropriations (one per page)

16. Specific lobbying issues

H. Con. Res. 95, Budget Reconciliation, pharmaceutical counterfeiting, importation
H.R. 2744, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2006, pharmaceutical counterfeiting, importation
H. R. 2862, Science, State, Justice, Commerce, and Related Agencies Appropriations Act, 2006, pharmaceutical counterfeiting, importation
H.R. 3010, Departments of Labor, Health and Human Services, and Education, and Related Agencies

17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

	Name	Covered Official Position (if applicable)
Richard H.	Bagger	
Catherine P.	Bennett	
Michael D.	Boyd	
Kimberly Miller	Davis	
Dolly	Judge	
Louis A.	LaMarca	
Justin	McCarthy	
Anne	Wilson	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

House of Representatives
Senate

0000061702

Registrant Name Pfizer Inc Client Name Pfizer Inc

ADDENDUM for General Lobbying Issue Area BUD

16. Specific lobbying issues (continued from previous page)

Appropriations Act, 2006, pharmaceutical counterfeiting, importation
S. Con. Res. 18, Budget reconciliation, pharmaceutical counterfeiting, importation

0000061703



Registrant Name Pfizer Inc

Client Name Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code CPT - Copyright/Patent/Trademark (one per page)

16. Specific lobbying issues

H.R. 328, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation
H.R. 700, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues
S. 109, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation
S. 334, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues

17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Richard H. Bagger	
Catherine P. Bennett	
Michael D. Boyd	
Kimberly Miller Davis	
Dolly Judge	
Louis A. LaMarca	
Justin McCarthy	
Anne Wilson	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

House of Representatives
Senate

0000061704

9

Registrant Name Pfizer Inc

Client Name Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code CSP - Consumer Issues/Safety/Protection (one per page)

16. Specific lobbying issues

H.R. 2090, The Food and Drug Administration Improvement Act of 2005, drug safety
H.R. 3196, The Fair Access to Clinical Trials ("FACT") Act of 2005, drug safety
H.R. 328, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation, drug safety
H.R. 700, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues

17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Richard H. Bagger	
Catherine P. Bennett	
Michael D. Boyd	
Kimberly Miller Davis	
Dolly Judge	
Louis A. LaMarca	
Justin McCarthy	
Anne Wilson	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

1000061705

Registrant Name Pfizer Inc Client Name Pfizer Inc

ADDENDUM for General Lobbying Issue Area CSP

16. Specific lobbying issues (continued from previous page)

H.R. 870, The PhRMA Research and Manufacturers Accountability (PhRMA) Act, drug safety
S. 109, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation
S. 334, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importat
patent issues
S. 470, The Fair Access to Clinical Trials ("FACT") Act of 2005, drug safety
S. 930, Food and Drug Administration Safety Act of 2005, drug safety

0000061706

Registrant Name Pfizer Inc

Client Name Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code HCR - Health Issues (one per page)

16. Specific lobbying issues

H.R. 328, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation
H.R. 700, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues
S. 109, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation
S. 334, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues

17. House(s) of Congress and Federal agencies contacted Check if None

Department of Health & Human Services
Executive Office of the President
Food and Drug Administration
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Richard H. Bagger	
Catherine P. Bennett	
Michael D. Boyd	
Christopher Carey	
Kimberly Miller Davis	
Dolly Judge	
Louis A. LaMarca	
Justin McCarthy	
Anne Wilson	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000061707

Registrant Name Pfizer Inc Client Name Pfizer Inc

ADDENDUM for General Lobbying Issue Area HCR

16. Specific lobbying issues (continued from previous page)

H.R. 3010, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2006, access to prescription drugs
 H.R. 3971, Social Services Emergency Relief and Recovery Act of 2005, access to prescription drugs

0000061708



Registrant Name Pfizer Inc

Client Name Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code MMM - Medicare/Medicaid (one per page)

16. Specific lobbying issues

H.R. 3010, Labor, HHS Appropriations, prescription drug benefit, price controls
H.R. 712, Medicare Prescription Drug Sensibility Act, prescription drug benefit
S. 1932, Deficit Reduction Omnibus Reconciliation Act, prescription drug payment issues
Medicare prescription drug benefit implementation (no bills)
Medicaid rebates (no bills)
Medicaid coverage (no bills)

17. House(s) of Congress and Federal agencies contacted Check if None

Department of Health & Human Services
Executive Office of the President
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Richard H. Bagger	
Catherine P. Bennett	
Christopher Carey	
Kimberly Miller Davis	
Dolly Judge	
Louis A. LaMarca	
Anne Wilson	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000061710

Registrant Name Pfizer Inc Client Name Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code SCI - Science/Technology (one per page)

16. Specific lobbying issues

H.R. 2122, The Project BioShield Act of 2003, pharmaceutical research and development, security

17. House(s) of Congress and Federal agencies contacted Check if None

Department of Commerce
Department of Health & Human Services
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Dolly Judge	
Louis A. LaMarca	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000061711



Registrant Name Pfizer Inc

Client Name Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code TAX - Taxation/Internal Revenue Code (one per page)

16. Specific lobbying issues

International repatriation tax (no bills)

17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Catherine P. Bennett	
Michael D. Boyd	
Justin McCarthy	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000061712



Registrant Name Pfizer Inc

Client Name Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code TOR - Torts (one per page)

16. Specific lobbying issues

S. 5, The Class Action Fairness Act of 2005, class action reform
S. 852, The Fairness in Asbestos Injury Resolution Act of 2005, asbestos litigation

17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Richard H. Bagger	
Catherine P. Bennett	
Michael D. Boyd	
Justin McCarthy	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

1000061713

Registrant Name Pfizer Inc

Client Name Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code TRD - Trade (Domestic & Foreign) (one per page)

16. Specific lobbying issues

H.R. 2862, Science, State, Justice Appropriations, market access
H.R. 3045, Dominican Republic-Central America-United States Free Trade Agreement Implementation Act, intellectual property, foreign price controls, market access restrictions
H.R. 3283, Agreement The United States Trade Rights Enforcement Act of 2005, intellectual property, market access, foreign price controls
S. 307, Agreement The United States Trade Rights Enforcement Act of 2005, intellectual property,

17. House(s) of Congress and Federal agencies contacted Check if None

Department of Commerce
Department of State
Executive Office of the President
House of Representatives
Office of the U.S. Trade Representative
Senate

18. Name of each individual who acted as a lobbyist in this issue area

	Name	Covered Official Position (if applicable)
	Catherine P. Bennett	
	Michael D. Boyd	
	Justin McCarthy	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000061714



Registrant Name Pfizer Inc Client Name Pfizer Inc

ADDENDUM for General Lobbying Issue Area TRD

16. Specific lobbying issues (continued from previous page)

market access, foreign price controls
 Intellectual property protection, foreign price controls and other market access restrictions (no bills)
 International intellectual protection (no bills)
 International pharmaceutical market access (no bills)
 WTO accession and implementation issues (no bills)

0000061715

